

Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024

<https://marketpublishers.com/r/G10E2642083EN.html>

Date: November 2018

Pages: 1100

Price: US\$ 3,000.00 (Single User License)

ID: G10E2642083EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024' Report Highlights:

Significance for Monoclonal Antibodies for Cancer Treatment

Global Cancer Monoclonal Antibodies Market Overview

Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication

Global Cancer Monoclonal Antibodies Pipeline: 697 mAb

Marketed Cancer Monoclonal Antibodies: 60

Global Cancer Monoclonal Antibodies Market Opportunity: US\$ 140 Billion

The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system so as to

develop more efficient mAbs.

Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body's immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together. Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient's lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies.

Contents

1. INTRODUCTION TO MONOCLONAL ANTIBODIES

- 1.1 History of Development
- 1.2 Working of Monoclonal Antibodies

2. MONOCLONAL ANTIBODIES CLASSIFICATION

- 2.1 Naked Monoclonal Antibodies
- 2.2 Conjugated Monoclonal Antibodies
 - 2.2.1 Radiolabeled Antibodies
 - 2.2.2 Chemolabeled Antibodies
 - 2.2.3 Immunotoxins

3. MONOCLONAL ANTIBODIES MECHANISMS

- 3.1 Tumor Antigens as Targets of Antibodies
- 3.2 Development of Antibodies for Clinical Purposes
- 3.3 Complement Dependent Cytotoxicity (CDC)
- 3.4 Signal Transduction Changes

4. SIGNIFICANCE FOR MONOCLONAL ANTIBODIES FOR CANCER TREATMENT

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET OVERVIEW

- 5.1 Current Market Scenario
- 5.2 Clinical Pipeline Insight

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET FUTURE OUTLOOK

7. GLOBAL - BLADDER CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 7.1 Phase-I/II
- 7.2 Phase-II
- 7.3 Phase-III

8. MARKETED BLADDER CANCER MONOCLONAL ANTIBODIES CLINICAL

INSIGHT

8.1 Durvalumab (Imfinzi)

9. GLOBAL - BLOOD CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

9.1 Unknown

9.2 Research

9.3 Preclinical

9.4 Clinical

9.5 Phase-I

9.6 Phase-I/II

9.7 Phase-II

9.8 Phase-III

9.9 Preregistration

10. MARKETED BLOOD CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

10.1 Daratumumab (DARZALEX)

10.2 Ofatumumab (Arzerra)

10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)

10.4 Blinatumomab (Blincyto)

10.5 Elotuzumab (Empliciti)

10.6 Mogamulizumab (Poteligeo)

10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)

10.8 Brentuximab Vedotin (Adcetris)

10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)

10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)

10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)

10.12 Rituximab Biosimilar (Rixathon & Riximyo)

10.13 Gemtuzumab Ozogamicin (Mylotarg)

10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)

10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)

10.16 Rituximab Biosimilar (Novex)

10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)

10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)

10.19 Rituximab Biosimilar (Zytux)

- 10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
- 10.21 Rituximab Biosimilar (Maball)
- 10.22 Rituximab Biosimilar (Kikuzubam)
- 10.23 Rituximab Biosimilar (Mabtas)

11. GLOBAL - BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 11.1 Unknown
- 11.2 Research
- 11.3 Preclinical
- 11.4 Phase-I
- 11.5 Phase-II
- 11.6 Phase-III
- 11.7 Preregistration
- 11.8 Registered

12. MARKETED BREAST CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

- 12.1 Trastuzumab Subcutaneous (Herceptin SC)
- 12.2 Pertuzumab (Omnitarg & Perjeta)
- 12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)
- 12.4 Trastuzumab Emtansine (Kadcyla)
- 12.5 Trastuzumab Biosimilar (Vivitra)

13. GLOBAL BONE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 13.1 Phase-III

14. MARKETED BONE CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

- 14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)

15. GLOBAL - BRAIN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 15.1 Preclinical

- 15.2 Phase-I/II
- 15.3 Phase-III
- 15.4 Registered

16. MARKETED BRAIN CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

- 16.1 Dinutuximab (Unituxin)

17. GLOBAL - CERVICAL CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 17.1 Phase-I/II

18. GLOBAL - COLORECTAL CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 18.1 Unknown
- 18.2 Preclinical
- 18.3 Phase-I

19. GLOBAL - HEAD AND NECK CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 19.1 Preclinical
- 19.2 Phase-I/II
- 19.3 Phase-III

20. GLOBAL - LIVER CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 20.1 Phase-II

21. GLOBAL - KIDNEY CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 21.1 Preclinical
- 21.2 Phase-II
- 21.3 Phase-III

22. GLOBAL - SKIN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 22.1 Research
- 22.2 Preclinical
- 22.3 Phase-I
- 22.4 Phase-I/II
- 22.5 Phase-II/III
- 22.6 Phase-III
- 22.7 Preregistration

23. MARKETED SKIN CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

- 23.1 Avelumab (BAVENCIO)
- 23.2 Olaratumab (Lartruvo)

24. GLOBAL - STOMACH CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 24.1 Preclinical
- 24.2 Phase-I/II
- 24.3 Phase-II
- 24.4 Phase-III
- 24.5 Preregistration

25. MARKETED STOMACH CANCER MONOCLONAL ANTIBODIES CLINICAL

- 25.1 Bevacizumab Biosimilar (Bevax)
- 25.2 Cetuximab Biosimilar – CinnaGen
- 25.3 Bevacizumab Biosimilar (Cizumab)

26. GLOBAL - LUNG CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 26.1 Research
- 26.2 Clinical
- 26.3 Phase-I
- 26.4 Phase-I/II
- 26.5 Phase-II

- 26.6 Phase-II/III
- 26.7 Phase-III
- 26.8 Preregistration
- 26.9 Registered

27. MARKETED LUNG CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

- 27.1 Necitumumab (Portrazza)
- 27.2 Iodine I 131 Derlotuximab Biotin (Cotara)
- 27.3 Bevacizumab Biosimilar (Bryxta)
- 27.4 Racotumomab (Vaxira)
- 27.5 Racotumomab (Vaxira)
- 27.6 Tc 99m Nofetumomab Merpentan (VerLuma)

28. GLOBAL - OVARIAN CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 28.1 Research
- 28.2 Preclinical
- 28.3 Phase-I
- 28.4 Phase-I/II
- 28.5 Phase-II

29. GLOBAL - PANCREATIC CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

- 29.1 Preclinical
- 29.2 Phase-I
- 29.3 Phase-I/II
- 29.4 Phase-II

30. MARKETED PANCREATIC CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

- 30.1 Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

31. GLOBAL - PROSTATE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

31.1 Preclinical

31.2 Phase-II

32. GLOBAL - MULTIPLE CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY & PHASE

32.1 Unknown

32.2 Research

32.3 Preclinical

32.4 Clinical

32.5 Phase-I

32.6 Phase-I/II

32.7 Phase-II

32.8 Phase-II/III

32.9 Phase-III

32.10 Registered

33. MARKETED MULTIPLE CANCER MONOCLONAL ANTIBODIES CLINICAL INSIGHT

33.1 Cetuximab (Erbitux)

33.2 Nivolumab (Opdivo)

33.3 Bevacizumab (Avastin)

33.4 Trastuzumab (Herceptin)

33.5 Atezolizumab (TECENTRIQ)

33.6 Rituximab (MabThera & Rituxan)

33.7 Ramucirumab (Cyramza, Sairamza & Silamza)

33.8 Trastuzumab Biosimilar (Herzuma)

33.9 Pembrolizumab (Keytruda)

33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)

33.11 Ipilimumab (Yervoy)

33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)

33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)

33.14 Bevacizumab Biosimilar (KRABEVA)

33.15 Bevacizumab Biosimilar (Mvasi)

33.16 Trastuzumab Biosimilar (AryoTrust)

33.17 Satumomab (OncoScint CR/OV)

34. COMPETITIVE LANDSCAPE

34.1 Abbvie

34.2 Amgen

34.3 Bayer HealthCare

34.4 Biogen Idec

34.5 Eli Lilly

34.6 Genmab

34.7 Gilead Sciences

34.8 GlaxoSmithKline

34.9 Novartis

34.10 Pfizer

34.11 Roche

34.12 Seattle Genetics

List Of Figures

LIST OF FIGURES

Figure 1-1: History of Development of Monoclonal Antibodies

Figure 1-2: Working of Monoclonal Antibodies

Figure 2-1: Types of Monoclonal Antibodies

Figure 5-1: Global Biologics Market Classification

Figure 5-2: Global Market for Monoclonal Antibodies (US\$ Billion), 2018-2024

Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-5: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-6: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-7: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-8: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-9: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-10: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-11: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-12: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-13: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-14: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-15: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-16: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-17: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-18: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-19: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-20: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-21: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-22: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-23: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-24: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-25: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-26: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-27: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-28: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-29: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-30: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-31: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-32: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-33: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-34: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

I would like to order

Product name: Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024

Product link: <https://marketpublishers.com/r/G10E2642083EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G10E2642083EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970